NYSE American - Nasdaq Real Time Price
USD
Calidi Biotherapeutics, Inc. (CLDI)
0.7001
+0.0211
(+3.11%)
At close: November 6 at 3:19:24 PM EST
0.7649
+0.0849
(+12.49%)
Pre-Market: 7:49:48 AM EST
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Eric E. Poma Ph.D.
|
CEO & Director | 565.61k | -- | 1972 |
|
Mr. Andrew C. Jackson
|
CFO & Corporate Secretary | 557.63k | -- | 1969 |
|
Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D.
|
Head of Technical Operations & Chief Scientific Officer | -- | -- | 1980 |
|
Dr. Guy Travis Clifton M.D.
|
Chief Medical Officer | -- | -- | -- |
Calidi Biotherapeutics, Inc.
4475 Executive Drive
Suite 200
San Diego, CA 92121
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 29
Description
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Corporate Governance
Calidi Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
